Figure 5

Further validation of the prognostic model in the internal validation set 1. (A) 5-year survival ROC curve for the internal validation set with an AUC value of 0.612. (B) Group division. (C) Distributions of survival time and status. (D) Distributions of model genes' expression. (E) Prognostic performances of our-established model. (F) Assessment of immunocyte infiltration distributions. (G–J) The differences in ESTIMATE score, immune score, stromal score, tumor purity in the low-risk and high-risk subgroups in the internal validation set 1.